Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2014

Open Access 01-02-2014 | Research article

Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study

Authors: Maria Bokarewa, Mikael Brink, Malin Erlandsson, Solbritt Rantapää Dahlqvist

Published in: Arthritis Research & Therapy | Issue 1/2014

Login to get access

Abstract

Introduction

Antibodies against citrullinated peptides (anti-CCP) and increased levels of cytokines precede the development of rheumatoid arthritis (RA) by several years. Recently, the proteins survivin and Fms-like tyrosine kinase 3 ligand (Flt3L) have been identified as biomarkers of RA associated with joint destruction. Our objective was to investigate the potential of survivin and Flt3L as predictors of RA in samples from patients prior to onset of symptoms.

Methods

This study included 47 individuals sampled before onset of RA (median 2.5 years (IQR 4.5) and 155 matched controls, all were donors to the Medical Biobank of Northern Sweden, and 36 RA patients. Levels of anti-CCP, survivin and Flt3L were measured using ELISAs and 29 cytokines/chemokines by multiplex detection.

Results

Levels of survivin were increased in pre-symptomatic individuals compared with controls (P = 0.003), whilst the levels of Flt3L were similar. The frequency of survivin positivity in the pre-symptomatic individuals was increased compared with the controls (36.2 vs.14.2%, P = 0.001) and predicted disease development (odds ratio (OR) =3.4 (95% confidence interval (CI) 1.6-7.2)). The frequency of survivin and Flt3L in RA patients was increased compared with the controls (both, P <0.0001, OR = 12.1 (95% CI, 5.3-27.6) and OR = 11.0 (95% CI, 3.9-30.9), respectively). Anti-CCP positive pre-symptomatic individuals and patients had significantly higher levels of survivin compared with anti-CCP2 negative individuals. In pre-symptomatic individuals, survivin correlated with IL-12, IL-1β and IL-9 whereas Flt3L correlated to a significantly broader spectrum of cytokines in RA patients.

Conclusion

Proto-oncogene survivin was increased in individuals prior to onset of symptoms of RA and was correlated to cytokines suggesting its role at pre-clinical stages of the disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, Harrington AR, Kolfenbach JR, Striebich CC, Pham QN, Strickland CD, Petersen BD, Parish MC, Derber LA, Norris JM, Holers VM, Deane KD: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?. Arthritis Rheum. 2012, 64: 1756-1761.CrossRefPubMedPubMedCentral Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, Harrington AR, Kolfenbach JR, Striebich CC, Pham QN, Strickland CD, Petersen BD, Parish MC, Derber LA, Norris JM, Holers VM, Deane KD: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity?. Arthritis Rheum. 2012, 64: 1756-1761.CrossRefPubMedPubMedCentral
2.
go back to reference Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D: High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012, 44: 1336-1340. 10.1038/ng.2462.CrossRefPubMedPubMedCentral Eyre S, Bowes J, Diogo D, Lee A, Barton A, Martin P, Zhernakova A, Stahl E, Viatte S, McAllister K, Amos CI, Padyukov L, Toes RE, Huizinga TW, Wijmenga C, Trynka G, Franke L, Westra HJ, Alfredsson L, Hu X, Sandor C, de Bakker PI, Davila S, Khor CC, Heng KK, Andrews R, Edkins S, Hunt SE, Langford C, Symmons D: High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet. 2012, 44: 1336-1340. 10.1038/ng.2462.CrossRefPubMedPubMedCentral
3.
go back to reference Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006, 54: 38-46. 10.1002/art.21575.CrossRefPubMed Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, Ronnelid J, Harris HE, Ulfgren AK, Rantapaa-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L: A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006, 54: 38-46. 10.1002/art.21575.CrossRefPubMed
4.
go back to reference Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H, Ronnelid J, Klareskog L, Dahlqvist SR: Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013, 65: 899-910. 10.1002/art.37835.CrossRefPubMed Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H, Ronnelid J, Klareskog L, Dahlqvist SR: Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis Rheum. 2013, 65: 899-910. 10.1002/art.37835.CrossRefPubMed
5.
go back to reference Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.PubMed Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S: Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010, 62: 383-391.PubMed
6.
go back to reference Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed Rantapää-Dahlqvist S, de Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48: 2741-2749. 10.1002/art.11223.CrossRefPubMed
7.
go back to reference Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, Gilliland WR, Tibshirani RJ, Norris JM, Holers VM, Robinson WH: Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012, 7: e35296-10.1371/journal.pone.0035296.CrossRefPubMedPubMedCentral Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, Edison JD, Gilliland WR, Tibshirani RJ, Norris JM, Holers VM, Robinson WH: Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012, 7: e35296-10.1371/journal.pone.0035296.CrossRefPubMedPubMedCentral
8.
go back to reference Deane KD, O’Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, Holers VM: The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010, 62: 3161-3172. 10.1002/art.27638.CrossRefPubMedPubMedCentral Deane KD, O’Donnell CI, Hueber W, Majka DS, Lazar AA, Derber LA, Gilliland WR, Edison JD, Norris JM, Robinson WH, Holers VM: The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 2010, 62: 3161-3172. 10.1002/art.27638.CrossRefPubMedPubMedCentral
9.
go back to reference Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D, Schuh AC: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood. 2000, 95: 1435-1442.PubMed Conway EM, Pollefeyt S, Cornelissen J, DeBaere I, Steiner-Mosonyi M, Ong K, Baens M, Collen D, Schuh AC: Three differentially expressed survivin cDNA variants encode proteins with distinct antiapoptotic functions. Blood. 2000, 95: 1435-1442.PubMed
10.
go back to reference Svensson MN, Andersson SE, Erlandsson MC, Jonsson IM, Ekwall AK, Andersson KM, Nilsson A, Bian L, Brisslert M, Bokarewa MI: Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis. PLoS One. 2013, 8: e54884-10.1371/journal.pone.0054884.CrossRefPubMedPubMedCentral Svensson MN, Andersson SE, Erlandsson MC, Jonsson IM, Ekwall AK, Andersson KM, Nilsson A, Bian L, Brisslert M, Bokarewa MI: Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis. PLoS One. 2013, 8: e54884-10.1371/journal.pone.0054884.CrossRefPubMedPubMedCentral
11.
go back to reference Bokarewa M, Lindblad S, Bokarew D, Tarkowski A: Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R349-R358. 10.1186/ar1498.CrossRefPubMedPubMedCentral Bokarewa M, Lindblad S, Bokarew D, Tarkowski A: Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R349-R358. 10.1186/ar1498.CrossRefPubMedPubMedCentral
12.
go back to reference Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Tarkowski A: Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One. 2008, 3: e3633-10.1371/journal.pone.0003633.CrossRefPubMedPubMedCentral Dehlin M, Bokarewa M, Rottapel R, Foster SJ, Magnusson M, Dahlberg LE, Tarkowski A: Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis. PLoS One. 2008, 3: e3633-10.1371/journal.pone.0003633.CrossRefPubMedPubMedCentral
13.
go back to reference Svensson B, Hafstrom I, Forslind K, Albertsson K, Tarkowski A, Bokarewa M: Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med. 2010, 42: 45-54. 10.3109/07853890903376280.CrossRefPubMed Svensson B, Hafstrom I, Forslind K, Albertsson K, Tarkowski A, Bokarewa M: Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med. 2010, 42: 45-54. 10.3109/07853890903376280.CrossRefPubMed
14.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31: 315-324. 10.1002/art.1780310302.CrossRefPubMed
15.
go back to reference Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI: Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 2012, 7: e47668-10.1371/journal.pone.0047668.CrossRefPubMedPubMedCentral Andersson SE, Svensson MN, Erlandsson MC, Dehlin M, Andersson KM, Bokarewa MI: Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis. PLoS One. 2012, 7: e47668-10.1371/journal.pone.0047668.CrossRefPubMedPubMedCentral
16.
go back to reference Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR: A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004, 6: R303-R308. 10.1186/ar1187.CrossRefPubMedPubMedCentral Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, Klareskog L, Dahlqvist SR: A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004, 6: R303-R308. 10.1186/ar1187.CrossRefPubMedPubMedCentral
17.
go back to reference Erlandsson MC, Forslind K, Andersson SE, Lund A, Bokarewa MI: Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA. Rheumatol (Oxford). 2012, 51: 932-940. 10.1093/rheumatology/ker362.CrossRef Erlandsson MC, Forslind K, Andersson SE, Lund A, Bokarewa MI: Metastasin S100A4 is increased in proportion to radiographic damage in patients with RA. Rheumatol (Oxford). 2012, 51: 932-940. 10.1093/rheumatology/ker362.CrossRef
18.
go back to reference Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, Lund A, Bokarewa M: High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2012, 41: 652-657. 10.1016/j.semarthrit.2011.08.005.CrossRefPubMed Isgren A, Forslind K, Erlandsson M, Axelsson C, Andersson S, Lund A, Bokarewa M: High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2012, 41: 652-657. 10.1016/j.semarthrit.2011.08.005.CrossRefPubMed
19.
go back to reference Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, Mak TW: Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004, 199: 399-410. 10.1084/jem.20032092.CrossRefPubMedPubMedCentral Okada H, Bakal C, Shahinian A, Elia A, Wakeham A, Suh WK, Duncan GS, Ciofani M, Rottapel R, Zuniga-Pflucker JC, Mak TW: Survivin loss in thymocytes triggers p53-mediated growth arrest and p53-independent cell death. J Exp Med. 2004, 199: 399-410. 10.1084/jem.20032092.CrossRefPubMedPubMedCentral
20.
go back to reference Xing Z, Conway EM, Kang C, Winoto A: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004, 199: 69-80.CrossRefPubMedPubMedCentral Xing Z, Conway EM, Kang C, Winoto A: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004, 199: 69-80.CrossRefPubMedPubMedCentral
22.
go back to reference Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS: Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001, 76: 169-173. 10.1016/S0165-2478(01)00186-9.CrossRefPubMed Kornacker M, Verneris MR, Kornacker B, Scheffold C, Negrin RS: Survivin expression correlates with apoptosis resistance after lymphocyte activation and is found preferentially in memory T cells. Immunol Lett. 2001, 76: 169-173. 10.1016/S0165-2478(01)00186-9.CrossRefPubMed
23.
go back to reference Ahn JK, Oh JM, Lee J, Bae EK, Ahn KS, Cha HS, Koh EM: Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation. 2010, 33: 381-388. 10.1007/s10753-010-9196-1.CrossRefPubMed Ahn JK, Oh JM, Lee J, Bae EK, Ahn KS, Cha HS, Koh EM: Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Inflammation. 2010, 33: 381-388. 10.1007/s10753-010-9196-1.CrossRefPubMed
24.
go back to reference Baran M, Mollers LN, Andersson S, Jonsson IM, Ekwall AK, Bjersing J, Tarkowski A, Bokarewa M: Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med. 2009, 13: 3797-3808. 10.1111/j.1582-4934.2009.00721.x.CrossRefPubMedPubMedCentral Baran M, Mollers LN, Andersson S, Jonsson IM, Ekwall AK, Bjersing J, Tarkowski A, Bokarewa M: Survivin is an essential mediator of arthritis interacting with urokinase signalling. J Cell Mol Med. 2009, 13: 3797-3808. 10.1111/j.1582-4934.2009.00721.x.CrossRefPubMedPubMedCentral
25.
go back to reference Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR: Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther. 2009, 11: R13-10.1186/ar2603.CrossRefPubMedPubMedCentral Dharmapatni AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, Ahern MJ, Weedon H, Chen P, Screaton G, Xu XN, Haynes DR: Elevated expression of caspase-3 inhibitors, survivin and xIAP correlates with low levels of apoptosis in active rheumatoid synovium. Arthritis Res Ther. 2009, 11: R13-10.1186/ar2603.CrossRefPubMedPubMedCentral
26.
go back to reference Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ: Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatol (Oxford). 2010, 49: 862-875. 10.1093/rheumatology/kep467.CrossRef Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ: Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatol (Oxford). 2010, 49: 862-875. 10.1093/rheumatology/kep467.CrossRef
27.
go back to reference van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, de Vries N, van Schaardenburg D, Dijkmans BA, Gerlag DM, Tak PP: Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011, 70: 772-777. 10.1136/ard.2010.139527.CrossRefPubMed van de Sande MG, de Hair MJ, van der Leij C, Klarenbeek PL, Bos WH, Smith MD, Maas M, de Vries N, van Schaardenburg D, Dijkmans BA, Gerlag DM, Tak PP: Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011, 70: 772-777. 10.1136/ard.2010.139527.CrossRefPubMed
28.
go back to reference Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A: Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood. 2009, 113: 6277-6287. 10.1182/blood-2008-06-161026.CrossRefPubMed Swee LK, Bosco N, Malissen B, Ceredig R, Rolink A: Expansion of peripheral naturally occurring T regulatory cells by Fms-like tyrosine kinase 3 ligand treatment. Blood. 2009, 113: 6277-6287. 10.1182/blood-2008-06-161026.CrossRefPubMed
29.
go back to reference Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M: Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol. 2011, 90: 811-817. 10.1189/jlb.1110640.CrossRefPubMed Dehlin M, Andersson S, Erlandsson M, Brisslert M, Bokarewa M: Inhibition of fms-like tyrosine kinase 3 alleviates experimental arthritis by reducing formation of dendritic cells and antigen presentation. J Leukoc Biol. 2011, 90: 811-817. 10.1189/jlb.1110640.CrossRefPubMed
32.
go back to reference Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604. 10.1016/j.immuni.2010.05.007.CrossRefPubMed Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604. 10.1016/j.immuni.2010.05.007.CrossRefPubMed
33.
go back to reference Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R: Control systems and decision making for antibody production. Nat Immunol. 2010, 11: 681-688.CrossRefPubMed Goodnow CC, Vinuesa CG, Randall KL, Mackay F, Brink R: Control systems and decision making for antibody production. Nat Immunol. 2010, 11: 681-688.CrossRefPubMed
Metadata
Title
Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study
Authors
Maria Bokarewa
Mikael Brink
Malin Erlandsson
Solbritt Rantapää Dahlqvist
Publication date
01-02-2014
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2014
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4474

Other articles of this Issue 1/2014

Arthritis Research & Therapy 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.